Stratified medicine for acute and chronic coronary syndromes: A patient-tailored approach

Rocco A Montone1, Thomas J Ford2, Mattia Galli3

  • 1Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Insights

Precision medicine revolutionizes cardiovascular disease care by moving beyond "one-size-fits-all" treatments. Identifying specific patient endotypes using biomarkers and advanced diagnostics enables tailored therapies for ischemic heart disease.

Area of Science:

  • Cardiovascular Medicine
  • Genomics and Precision Health

Background:

  • Traditional cardiovascular disease management uses uniform treatment pathways based on symptoms.
  • This "one-size-fits-all" approach may not optimize outcomes for all patients.
  • The need for personalized treatment strategies is increasingly recognized.

Purpose of the Study:

  • To review strategies for applying stratified management in acute and chronic coronary syndromes.
  • To explore the integration of multi-omics data with traditional clinical information for precision medicine.
  • To highlight the role of biomarkers and intravascular assessment in identifying distinct endotypes.

Main Methods:

  • Review of current literature on precision medicine in cardiology.
  • Discussion of multi-omics technologies and their application in identifying disease endotypes.
  • Analysis of biomarkers and intravascular assessment techniques for patient stratification.

Main Results:

  • Biomarkers and intravascular assessments can differentiate endotypes within ischemic heart disease.
  • These endotypes exhibit distinct pathophysiologies, suggesting varied treatment responses.
  • Stratified management holds promise for optimizing treatment in coronary syndromes.

Conclusions:

  • Precision medicine offers a paradigm shift from uniform to tailored cardiovascular care.
  • Identifying patient endotypes is crucial for effective stratified management of coronary syndromes.
  • Integrating diverse data sources, including multi-omics, is key to advancing precision cardiology.

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
571
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.2K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
87
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419